News

  1. FDA: 35 Innovative New Drugs Approved In Fiscal Year 2011 11/4/2011
    Over the past 12 months, the U.S. Food and Drug Administration approved 35 new medicines.
  2. Novartis Achieves Strong Third Quarter Financial Performance And Pipeline Progress 10/28/2011
    Novartis is announcing recently additional cost reduction activity, which will be executed over three to five years. Elements of the activity to include: reallocation of production within the Novartis network resulting in closure of two sites in Switzerland and one in Italy; restructuring the development organization largely in Switzerland and the US and relocating some research activities from Switzerland to the US.
  3. Merck Announces Presentation Of Phase III Investigational Studies Evaluating DULERA® (Mometasone Furoate And Formoterol Fumarate Dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD) 10/27/2011
    Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD).
  4. FDA Approves Remicade To Treat Ulcerative Colitis In Children 6 Years And Older 9/30/2011
    The U.S. Food and Drug Administration recently approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children 6 years and older who have had inadequate response to conventional therapy.
  5. Novartis Drug Afinitor Effective In Patients With Non-Cancerous Kidney Tumors Associated With TSC In Phase III Trial 9/26/2011
    A Phase III study of Afinitor (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.
  6. Roche Researchers Sequence Complete Genome Of Cynomolgus Monkey And Develop Novel Gene Expression Microarray For Drug Safety Assessment 9/23/2011
    A team of researchers from Roche including scientists from Roche Pharma Research and Early Development and Roche NimbleGen, reported in Genome Research that they have generated the first draft genome sequence of the cynomolgus monkey (Macaca fascicularis) and developed a novel microarray design for in depth expression profiling for use in preclinical drug safety research.
  7. HemoShear Awarded $4.3M NIH Grant To Develop Predictive Drug Database 9/2/2011
    HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, recently announced that it has been awarded up to $4.3M in a Phase II Small Business Innovation Research (SBIR) grant award from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
  8. MakroCare, LSK Global Sign Alliance Agreement 8/23/2011
    MakroCare, an international Drug Development and Commercialization services firm, and LSK Global, a Korean CRO headquartered in Seoul, recently announced the signing of an alliance agreement.
  9. Mark Sneff Named Vice President, Human Resources At Premier Research Group 8/3/2011
    Premier Research Group Limited announces the appointment of Mark P. Sneff to the position of Vice President, Human Resources.
  10. New Survey From Blue Chip Patient Recruitment Reveals Best Practices For Using Social Media In Clinical Trials 7/25/2011
    Blue Chip Patient Recruitment, a division of global, full-service marketing agency Blue Chip Marketing Worldwide, has authored a white paper advising patient recruitment specialists on how to effectively implement social media into their recruitment strategies.